Zurich, SWITZERLAND 06. July 2017 -- Sequana Medical AG (“Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled trial in the Journal of Hepatology (http://www.journal-of-hepatology.eu/article/S0168-8278(17)32080-9/ppt).
The study demonstrated that in patients with refractory ascites, the alfapump®:
- significantly reduces the requirement for LVP compared to standard of care
- significantly improves Health-Related Quality of Life compared to standard of care
- shows nutritional benefits compared to standard of care